HIV and Cardiovascular Health: Understanding the Increased Risk
For individuals living with HIV, maintaining overall health extends beyond managing the virus itself. A growing body of research highlights a significant link between HIV and an increased risk of cardiovascular disease (CVD). This article explores the complexities of this connection, the factors contributing to it, and the latest advancements in prevention and management.
The Link Between HIV and Cardiovascular Disease
People with HIV (PWH) demonstrate up to twice the risk for cardiovascular disease compared to those without HIV, even with consistent antiretroviral therapy (ART).[1] This heightened risk encompasses conditions like myocardial infarction (heart attack), heart failure, and sudden cardiac death. The increased prevalence of coronary artery disease is as well observed in individuals with well-controlled HIV. [3]
Why is There an Increased Risk?
The reasons behind this increased risk are multifaceted and not fully understood. Several factors are believed to contribute:
- Chronic Inflammation: HIV itself triggers chronic inflammation, even in individuals on ART. This inflammation plays a key role in the development of atherosclerosis – the buildup of plaque in the arteries. [4]
- Immune Activation: Persistent immune activation, a hallmark of HIV infection, contributes to vascular inflammation and plaque formation. [3]
- Traditional Risk Factors: PWH may have a higher prevalence of traditional CVD risk factors like tobacco smoking.[2]
- Antiretroviral Therapy (ART): Whereas ART is crucial for managing HIV, some older ART regimens were associated with metabolic abnormalities (like high cholesterol and insulin resistance) that could increase CVD risk. But, newer ART formulations have improved metabolic profiles.
- HIV-Specific Factors: The nature of CVD in HIV is not clearly linked to traditional risk factors or ART, suggesting unique pathways are involved.[2]
Coronary Plaque and Inflammation
Research indicates that approximately half of individuals with HIV have coronary plaque, even with well-controlled viral loads and moderate or low traditional risk factors. [3] The presence of this plaque is associated with higher levels of markers indicating immune function and inflammation.
Prevention and Management Strategies
Several strategies are being employed to reduce CVD risk in PWH:
- Pitavastatin: The REPRIEVE trial demonstrated that daily pitavastatin calcium significantly lowered the risk of major adverse cardiovascular events (MACE) in PWH.[2] (Hazard ratio, 0.65; 95% CI, 0.48-0.90; P =.002).
- Lifestyle Modifications: Smoking cessation, a healthy diet, and regular exercise are crucial for all individuals, but particularly important for PWH.
- Management of Traditional Risk Factors: Aggressive management of blood pressure, cholesterol, and blood sugar is essential.
- Allergen Immunotherapy: Research suggests allergen immunotherapy may be safe and effective in HIV+ patients with allergic respiratory diseases, potentially improving quality of life.[1]
The Role of Allergies and Immune Response
HIV attacks the central control mechanisms of the immune response, leading to opportunistic infections and malignancies. However, immune-based hypersensitivity diseases, including IgE-mediated conditions like allergies, are also common in PWH, often appearing before significant immunodeficiency.[1] Drug sensitivities are notably higher in this population.
Looking Ahead
Ongoing research continues to unravel the complex interplay between HIV and CVD. Further studies are needed to fully elucidate the mechanisms driving this increased risk and to develop targeted prevention and treatment strategies. For individuals living with HIV, proactive cardiovascular risk assessment and management are essential components of comprehensive care.